Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:17
  • preuzimanja u poslednjih 30 dana:3

Sadržaj

članak: 8 od 151  
Back povratak na rezultate
2020, vol. 59, br. 2, str. 38-46
Prediktivni značaj morfometrijske analize tripl negativnog karcinoma dojke
aUniverzitet u Nišu, Medicinski fakultet, Katedra Patologija
bKlinički centar Niš, Klinika za onkologiju
cUniverzitet u Nišu, Medicinski fakultet, Katedra Mikrobiologija i imunologija
dUniverzitet u Nišu, Medicinski fakultet, Katedra Hirurgija
eUniverzitet u Nišu, Medicinski fakultet, Katedra Farmakologija sa toksikologijom

e-adresanikola.zivkovic@medfak.ni.ac.rs
Projekat:
Virtuelni koštano zglobni sistem čoveka i njegova primena u pretkliničkoj i kliničkoj praksi (MPNTR - 41017)
We would like to thank for the internal project of the Faculty of Medicine in Niš - "Tumor-infiltrating Lymphocytes (TIL) as a Predictive and Prognostic Parameter after Neoadjuvant Therapy in Two Subtypes of Breast Cancer - Triple Negative and HER2 Positive" (No. 9).

Ključne reči: tripl negativni karcinom dojke; imunohistohemija; morfometrija
Sažetak
Tripl negativni karcinomi dojke predstavljaju maligne epitelne tumore koji pokazuju kompletnu hormonsku nezavisnost od negativne HER2 ekspresije. Histološki, u najvećem broju slučajeva, reč je o tumorima visokog gradusa, koji pokazuju polja centralne nekroze, limfocitnu infiltraciju i fibrozu. Cilj istaživanja zasniva se na ispitivanju morfometrijskih parametara, koji se odnose na veličinu jedra u zavisnosti od tipa karcinoma, kao i na proliferaciju tumora. Celokupno istraživanje sprovedeno je u Centru za patologiju i patološku anatomiju Kliničkog centra Niš. Analizirano je 64 biopsijska uzorka trostruko negativnih karcinoma dojke, i to 40 duktalnih, 6 lobularnih, 6 medularnih, 4 duktulolobularna, 4 metaplastična, 2 adenoidno cistična i 2 apokrina karcinoma. Morfometrijska analiza vršena je u softverskom paketu "ImageJ" verzija 1.52a. Statisitička analiza podataka rađena je u programskom paketu SPSS 15.0. Poređenjem vrednosti ispitivanih morfometrijskih parametara ustanovljene su statistički značajno više vrednosti parametara za površinu, obim i Feretov dijametar uzoraka grupe medularnih karcinoma, kao i parametra za Integrisanu optičku gustinu uzoraka iste grupe. Integrisana optička gustina bila je izrazito visoka i kod uzoraka u grupi duktalnih karcinoma, ali bez statistički značajne razlike zbog visoke standardne devijacije. Najveću proliferativnu aktivnost imao je metaplastični karcinom. Brojna istraživanja, slična ovom, pokušavaju da identifikuju specifičan marker ovih karcinoma, koji zbog velike agresivnosti i danas predstavlja izazov. Reč je o tumorima širokog spektra polimorfizma, visokog gradusa, sa veoma često preklapajućom morfološkom prezentacijom, pa su dodatne analize neophodne u cilju postavljanja adekvatne dijagnoze.
Reference
Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V.-M., Marin, S., Alhava, E., Syrjänen, K. (1992) Tumor size, nuclear morphometry, mitotic indices as prognostic factors in axillary-lymph-node-positive breast cancer. European Surgical Research, 24(3): 160-168
Abdalla, F., Boder, J., Markus, R., Hashmi, H., Buhmeida, A., Collan, Y. (2009) Correlation of nuclear morphometry of breast cancer in histological sections with clinicopathological features and prognosis. Anticancer Res, 29: 1771-6
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., Birnbaum, D. (2008) How basal are triple-negative breast cancers?. International Journal of Cancer, 123(1): 236-240
Bidard, F.-C., Conforti, R., Boulet, T., Michiels, S., Delaloge, S., André, F. (2007) Does triple-negative phenotype accurately identify basal-like tumour?: An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Annals of Oncology, 18(7): 1285-1286
Boyle, P. (2006) The globalisation of cancer. Lancet, 368(9536): 629-630
Brenton, J.D., Carey, L.A., Ahmed, A.A., Caldas, C. (2005) Molecular classification and molecular forecasting of breast cancer: Ready for clinical application?. Journal of Clinical Oncology, 23(29): 7350-7360
Burstein, M.D., Tsimelzon, A., Poage, G.M., Covington, K.R., Contreras, A., Fuqua, S.A.W., Savage, M.I., Osborne, C.K., Hilsenbeck, S.G., Chang, J.C., Mills, G.B., Lau, C.C., Brown, P.H. (2015) Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Research, 21(7): 1688-1698
Cleator, S., Heller, W., Coombes, R. C. (2007) Triple-negative breast cancer: Therapeutic options. Lancet Oncology, 8(3): 235-244
Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., Sawka, C.A., Lickley, L.A., Rawlinson, E., Sun, P., Narod, S.A. (2007) Triple-negative breast cancer: Clinical features and patterns of recurrence. Clinical Cancer Research, 13(15): 4429-4434
Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., Trotti, A. (2010) AJCC cancer staging manual. New York: Springer
Farhadian, M., Mahjub, H., Poorolajal, J., Moghimbeigi, A., Mansoorizadeh, M. (2014) Predicting 5-year survival status of patients with breast cancer based on supervised wavelet method. Osong Public Health and Research Perspectives, 5(6): 324-332
Fisher, B., Anderson, S., Redmond, C.K., Wolmark, N., Wickerham, D. L., Cronin, W.M. (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. New England Journal of Medicine, 333(22): 1456-1461
Fragomeni, S.M., Sciallis, A., Jeruss, J.S. (2018) Molecular subtypes and local-regional control of breast cancer. Surgical Oncology Clinics of North America, 27(1): 95-120
Freedman, G.M., Fowble, B.L. (2000) Local recurrence after mastectomy or breast-conserving surgery and radiation. Oncology, 14(11): 1561-81, Williston Park
Giardina, C., Renzulli, G., Serio, G., Caniglia, D.M., Lettini, T., Ferri, C., et al. (1996) Nuclear morphometry in node-negative breast carcinoma. Anal Quant Cytol Histol, 18: 374-82
Giuliano, A.E., Connolly, J.L., Edge, S.B., Mittendorf, E.A., Rugo, H.S., Solin, L.J., Weaver, D.L., Winchester, D.J., Hortobagyi, G.N. (2017) Breast cancer: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians, 67(4): 290-303
Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thürlimann, B., Senn, H.-J. (2011) Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology, 22(8): 1736-1747
Harvey, J.M., Clark, G.M., Osborne, C. K., Allred, D. C. (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology, 17(5):1474-81
Herschkowitz, J.I., Simin, K., Weigman, V.J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K.E., Jones, L.P., Assefnia, S., Chandrasekharan, S., Backlund, M.G., Yin, Y., Khramtsov, A.I., Bastein, R. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology, 8(5): R76-R76
Kalogeraki, A., Tamiolakis, D., Kozoni, V., Tzardi, M., Panayiotides, J., Melissas, J., et al. (2000) Nuclear grading in invasive ductal breast carcinomas. Cancer Detect Prev, 24:224-7
Lehmann, B.D., Jovanović, B., Chen, X., Estrada, M.V., Johnson, K.N., Shyr, Y., Moses, H.L., Sanders, M.E., Pietenpol, J.A. (2016) Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS One, 11(6): e0157368-e0157368
Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A. B., Shyr, Y., Pietenpol, J.A. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation, 121(7): 2750-2767
Moroz, K., Lipscomb, J., Vial, L.J. J., Dhurandhar, N. (1997) Cytologic nuclear grade of malignant breast aspirates as a predictor of histologic grade: Light microscopy and image analysis characteristics. Acta Cytol, 41:1107-11
Obedian, E., Haffty, B.G. (2000) Negative margin status improves local control in conservatively managed breast cancer patients. Cancer J Sci Am, 6(1): 28-33
Onitilo, A.A., Engel, J.M., Greenlee, R.T., Mukesh, B.N. (2009) Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clinical Medicine & Research, 7(1-2): 4-13
Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, Ø., Pergamenschikov, A., Williams, C., Zhu, S.X. (2000) Molecular portraits of human breast tumours. Nature, 406(6797): 747-752
Pienta, K.J., Coffey, D.S. (1991) Correlation of nuclear morphometry with progression of breast cancer. Cancer, 68(9): 2012-2016
Rosai, J. (2004) Rosai and Ackerman's surgical pathology. Philadelphia: Elsevier, pp. 1764-840
Schiff, R., Osborn, C.K., F.S. (2012) Clinical aspects of estrogen and progesterone receptors
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., Mcguire, W.L. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235(4785): 177-182
Trihia, H., Murray, S., Price, K., Gelber, R.D., Golouh, R., Goldhirsch, A., Coates, A.S., Collins, J., Castiglione-Gertsch, M., Gusterson, B.A., International Breast Cancer Study Group (2003) Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors: A surrogate marker?. Cancer, 97(5): 1321-31
Web, M.D. (2015) Types of breast cancer: ER positive, HER2 positive, and triple negative. http://www.webmd.com/breast-cancer/breast-cancer-types-er-positive-her2-positive (Accessed 27 Feb 2018)
Wolff, A.C., Hammond, M.E., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J., et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 131(1):18-43
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.5633/amm.2020.0205
objavljen u SCIndeksu: 02.09.2020.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0

Povezani članci